An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era

Incremental value in outcome prediction with gene expression-based signatures in diffuse large B-cell lymphoma

(2012) F. Hong et al.   BLOOD

Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database

(2012) A. S. LaCasce et al.   BLOOD

The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL

(2012) C. Muller et al.   BLOOD

Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma

(2012) W. Klapper et al.   BLOOD

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

(2011) G. Salles et al.   BLOOD

Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment

(2011) A. A. Alizadeh et al.   BLOOD

Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic in

(2010) Ranjana H. Advani et al.   BRITISH JOURNAL OF HAEMATOLOGY

Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era

(2010) Marita Ziepert et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab

(2010) Paul N. Meyer et al.   JOURNAL OF CLINICAL ONCOLOGY

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

(2009) K. J. Savage et al.   BLOOD

Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non-Hodgkin lymphoma (NHL) multicenter outcomes database

(2008) Michelle E. Kho et al.   CANCER

What Constitutes “Improved Prognosis”?

(2008) George P. Canellos   JOURNAL OF CLINICAL ONCOLOGY

Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma

(2008) Maria Christina Cox et al.   LEUKEMIA & LYMPHOMA

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE